文献速递膀胱癌与上尿路尿路上皮癌

美国泌尿外科学会非肌层浸润性膀胱癌风险模型验证——是否应将患者年龄加入风险模型?

American Urological Association Nonmuscle Invasive Bladder Cancer Risk Model Validation-Should Patient Age be Added to the Risk Model?
PubMed 文献 · J Urol · 2019-09-06

本研究基于美国多中心回顾性数据,评估AUA/SUO非肌层浸润性膀胱癌风险模型对复发和进展的预测效能,并分析4个年龄组的累积复发、进展和死亡发生率。共纳入1297例患者,中位随访3.2年,复发模型c-index为0.62,进展模型c-index为0.77。60岁以下患者5年内复发概率比死亡高40%,84岁及以上患者死亡概率比复发高12%。

要点

  • AUA/SUO复发模型c-index为0.62,进展模型c-index为0.77
  • 60岁以下患者5年内复发概率比死亡高40%
  • 84岁及以上患者5年内死亡概率比复发高12%

核心结论

  • AUA/SUO非肌层浸润性膀胱癌风险模型对复发和进展的预测效能与EORTC、CUETO和NCCN等既往类似风险模型相似。
  • 本研究提示临床医生在使用非肌层浸润性膀胱癌预测工具时应考虑年龄因素。

研究设计与样本

  • 回顾性分析,使用电子病历和癌症登记数据,纳入美国多中心非肌层浸润性膀胱癌患者人群。
  • 共纳入1297例非肌层浸润性膀胱癌患者,中位随访3.2年。
  • 按AUA/SUO非肌层浸润性膀胱癌风险模型评估无复发生存和无进展生存,使用c-index评估区分度,并比较4个年龄组的累积复发、进展和死亡发生率。

主要发现

  • AUA/SUO复发模型的c-index为0.62,进展模型的c-index更高,为0.77。
  • 60岁以下患者5年内复发概率比死亡高40%;84岁及以上患者5年内死亡概率比复发高12%。

临床怎么用

  • 作者认为,临床医生在使用非肌层浸润性膀胱癌预测工具时应考虑年龄因素。

局限性

  • 本研究受限于其回顾性设计。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: We evaluated the AUA (American Urological Association)/SUO (Society of Urologic Oncology) nonmuscle invasive bladder cancer risk model to predict nonmuscle invasive bladder cancer recurrence and progression prior to death. MATERIALS AND METHODS: We performed a retrospective analysis using electronic medical records and cancer registry data of patients with nonmuscle invasive bladder cancer in a multicenter United States patient population. We evaluated recurrence-free and progression-free survival according to the AUA/SUO nonmuscle invasive bladder cancer risk model. We then assessed discriminative performance with the c-index and compared the cumulative incidence of recurrence, progression and death across 4 age groups. RESULTS: We identified 1,297 patients with nonmuscle invasive bladder cancer. Median followup in the cohort was 3.2 years. The c-index of the AUA/SUO recurrence model was 0.62 and for progression it was higher at 0.77. Patients younger than 60 years had a 40% greater probability of recurrent nonmuscle invasive bladder cancer vs death while patients 84 years old or older had a 12% greater probability of death prior to recurrence at 5 years. This study was limited by its retrospective design. CONCLUSIONS: The AUA/SUO nonmuscle invasive bladder cancer risk model provides predictive performance of recurrence and progression similar to that of previous similar risk models, such as the models of the European Organization for Research and Treatment of Cancer, the Club Urológico Español de Tratamiento Oncológico and the National Comprehensive Cancer Network®. This work illustrates the need to consider age in predictive tools for clinicians who treat patients with nonmuscle invasive bladder cancer.

来源:J Urol,查看原文。版权归原作者所有。

引用

  1. Ravvaz K, Weissert JA, Downs TM, et al. American Urological Association Nonmuscle Invasive Bladder Cancer Risk Model Validation-Should Patient Age be Added to the Risk Model? J Urol. 2019. PMID: 31188732. doi:10.1097/JU.0000000000000389

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。